SG Americas Securities LLC lessened its position in shares of Repligen Corporation (NASDAQ:RGEN – Free Report) by 62.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 5,644 shares of the biotechnology company’s stock after selling 9,249 shares during the quarter. SG Americas Securities LLC’s holdings in Repligen were worth $665,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in RGEN. NewEdge Wealth LLC raised its position in shares of Repligen by 5.3% during the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 75 shares during the period. UMB Bank n.a. increased its stake in Repligen by 13.8% during the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 92 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in Repligen by 0.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after buying an additional 100 shares during the last quarter. Coldstream Capital Management Inc. lifted its stake in shares of Repligen by 5.3% in the fourth quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after buying an additional 101 shares in the last quarter. Finally, Itau Unibanco Holding S.A. grew its holdings in shares of Repligen by 38.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 104 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Repligen Price Performance
RGEN stock traded down $0.35 during trading on Tuesday, reaching $141.11. The company’s stock had a trading volume of 12,680 shares, compared to its average volume of 980,766. The company’s fifty day moving average is $124.38 and its 200-day moving average is $134.49. The company has a market capitalization of $7.96 billion, a P/E ratio of 156.52, a price-to-earnings-growth ratio of 2.74 and a beta of 1.06. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $175.77. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26.
Analyst Ratings Changes
Several analysts have recently commented on RGEN shares. Citigroup upgraded shares of Repligen to a “buy” rating in a report on Tuesday. Barclays upped their price objective on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Royal Bank Of Canada assumed coverage on Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective for the company. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a research note on Tuesday. Finally, HC Wainwright lifted their price objective on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $165.00.
View Our Latest Stock Report on Repligen
Insider Buying and Selling at Repligen
In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.60% of the company’s stock.
Repligen Profile
Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.
The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.
Read More
- Five stocks we like better than Repligen
- Big Beautiful Boycott: Can It Really Hurt Coca-Cola, Amazon, and Kraft Heinz Stocks?
- 3 Stocks With Solid Yields and Sustainabale Payouts Boost Dividends Once Again
- 2 Short Squeezes for Summer Speculation: What the Bears Are Getting Wrong
- How TeraWulf’s Anthropic Deal Booted Up a $19B AI Empire
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
